IM Cannabis Corp. (NASDAQ: IMCC) (CSE: IMCC) - Investor Dashboard


IM Cannabis Corp.
NASDAQ Ticker: IMCC
CSE Ticker: IMCC
Market Focus: Global
Classification: Vertically Integrated
Country: Israel
Employees: 200 as of 4/26/21
Established: 2010
CEO: Oren Shuster

IM Cannabis – Management Team


Oren Shuster – CEO and Director

One of Israel’s prominent experts in the field of medical cannabis, Oren brings more than two decades of proven entrepreneurial experience in founding and growing companies in the med-tech and technology/software industries. Prior to IMC, Oren co-founded E-wave with a vision to create an international tech company that provides software solutions for enterprises in digital, IT, HR, and medical technologies. His vision was realized fully and today, E-wave is a global software house that employs 1,000 professionals with operations in the U.S., Canada, Brazil, India, and Israel. In addition to a tremendously successful entrepreneurial track-record, he also has also held executive positions at companies within the telecom and digital media industries.Oren brings deep experience and understanding about where healthcare, patient care, technology and innovation intersect.

Marc Lustig – Executive Chairman

Marc Lustig is a highly regarded entrepreneur in the global legal cannabis industry and a capital markets veteran with a deep understanding of the pharmaceutical and life sciences sectors. Marc holds MSc and MBA degrees from McGill University. He began his professional career in the pharmaceutical industry at Merck & Co. In 2000, he started his capital markets career in institutional equity research in the Life Sciences sector at Orion Securities. For the next 14 years, Mr. Lustig worked at GMP Securities L.P. and as Head of Capital Markets at Dundee Capital Markets before becoming a Principal at KES7 Capital. In 2015 Mr. Lustig founded CannaRoyalty Corp. (Origin House). As the Chairman/CEO of Origin House, he spearheaded the 2020 landmark merger of the company with Cresco Labs Inc. one of U.S.’s largest multistate cannabis operators. In addition to his role as Executive Chairman on the IM Cannabis board, Marc also serves on the boards of both recreational and medical cannabis companies including Cresco Labs, PharmaCielo Ltd, Trichome Financial Corp. and Aequus Pharmaceuticals Inc.

Richard Balla – CEO and Director, Germany – Adjupharm GmbH

Richard Balla is the CEO of Adjupharm, IMC’s fully-owned German subsidiary and the company’s main European hub. For nearly two decades, Richard has brought his strategic business mindset to senior roles within the German pharmaceutical industry with a specialty in manufacturing, distribution, sales, and the parallel import of pharmaceuticals, medical devices, and cosmetics. He brings a unique professional background and experience in the German medical cannabis sector. This deep knowledge ensures market entry and expansion understanding to support IMC’s growth plans in Germany and other European jurisdictions that are on the verge of medical cannabis legalization. Prior to leading Adjupharm, Richard acted as a founder, early-stage shareholder, advisor and director of multiple international companies in the pharmaceutical and medical cannabis sectors. Before his entrepreneurial career, Richard served as Head of Market and Product Development at ACA Müller Pharma AG, one of the first and leading Parallel Import companies in Germany. In this role, he was responsible for ACA’s portfolio of 2000 branded pharmaceutical products, which were distributed to German wholesalers and pharmacies. Richard holds a Bachelor of Business Administration Degree from Gewerbe-Akademie Konstanz.

Shai Shemesh – Chief Financial Officer

Shai brings 15 years of international operational and financial experience to his role as IMC’s Chief Financial Officer. His sector understanding spans across pharmaceutical, infrastructure, energy, and professional services. Prior to joining IMC, Shai led all financial and operational management areas at Sadyt Israel and IVM Minrav-Sadyt, an international multi-million-dollar Israeli infrastructure project for water desalination. Shai also brings a wealth of financial and auditing experience from the pharmaceutical and professional services sectors, where he acted as a Financial Controller at Boston Scientific and as a Supervisor Auditor at PwC in Israel. Shai is a Certified Public Accountant (Isr.) and holds Master’s degree in Business Administration from IE Business School in Spain and a BA degree from the Tel Aviv University.

Yael Harrosh – General Counsel

Yael is an experienced lawyer with specific expertise in corporate law and civil litigation. As IMC’s General Counsel and Corporate Secretary, Yael played an instrumental role in IMC’s successful public listing on the Canadian Security Exchange (CSE). As a member of the senior management team, Yael oversees all corporate legal and compliance affairs and is responsible for the Company’s reporting obligations and regulatory compliance. Yael’s professional career crosses both the legal and marketing industries. Beforeofre joining IMC, Yael acted as in-house counsel and deputy CEO at Promarket Group, Israel’s largest experiential marketing company. Prior to Promarket, Yael applied her commercial law knowledge and litigation expertise at two leading Israeli law firms. Yael’s vast knowledge and experience in legal affairs related to medical cannabis is a key asset that informs IMC’s global growth strategy and execution. Yael graduated cum laude from the Faculty of Law with a Minor in Psychology from the Hebrew University of Jerusalem.

Michael Ruscetta – Co-Head North America

Mr. Ruscetta joined Trichome Financial in 2018 as Chief Executive Officer. Michael Ruscetta boasts over 25 years of direct investing experience in public and private equity, credit and distressed opportunities. He has formerly managed a private investing fund, after having worked in senior investing roles with Goldman Sachs (Special Situations Group), Amaranth Advisors, and CIBC Capital Partners. MBA (Ivey Business School) and BA (University of Toronto).

Howard Steinberg – Co-Head North America

Mr. Steinberg joined Trichome Financial board of directors in 2019 and was appointed CEO of Trichome JWC Acquisition Corp in 2020. With over 25 years experience as an operationally focused executive and investor in restructurings, private credit, private equity and real estate, Mr Steinberg has previously held key executive levels roles at Fortress Investment Group, GE Capital, RBC Capital Partners and The Rose Corporation. He founded Revest Asset Management (real estate), and was the executive chairman of Parallax Development Corp (life sciences) and Chairman of MYM Nutraceuticals (cannabis). CFA, MBA (Ivey Business School).

Significant Insider Ownership


Oren Shuster, CEO
9.1 million shares and 562K options

Michael Ruscetta, Co-Head North America
655K shares and 233K options

Howard Steinberg, Co-Head North America
336K shares shares and 562K options

Marc Lustig, Executive Chairman
1.3 million shares, 49K warrants and 675K options

Rafael Gabay, Co-Founder
8.1 million shares and 90K options


Visit IM Cannabis Corp.
at www.imcannabis.com

New Cannabis Ventures in partnership with due diligence platform 420Investor, is the definitive source for fact-based, data-driven, financial information and relevant company news for qualified publicly traded cannabis companies. NCV extracts and parses only the most important content. Information is provided “as is” and solely for informational purposes, not for trading or advice. IM Cannabis Corp. is a client of NCV Media, LLC. Read our full disclaimer.